Vaxzevria vaccine boosts mucosal immunity in COVID-19 recovered

Study highlights the ability of the Vaxzevria vaccine in inducing robust mucosal antibody responses, especially in COVID-19-recovered individuals, showcasing a notable defense against various SARS-CoV-2 variants. However, it emphasizes the need for booster doses to enhance anti-SARS-CoV-2 mucosal immunity, especially in infection-naïve individuals, to broaden protection against emerging viral variants.

Related Keywords

, Cell Biology , Coronavirus Disease Covid 19 , Immunity , Antibodies , Ntibody , Fell , Coronavirus , Efficacy , C Receptor , Mmunoglobulin , Mmunology , Protein , Eceptor , Espiratory , Cars , Ars Cov 2 , Evere Acute Respiratory , Evere Acute Respiratory Syndrome , Spike Protein , Yndrome , Throat , Vaccine , Virus ,